Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation - PubMed (original) (raw)

Review

Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation

Xing-Chun Wang et al. World J Gastroenterol. 2014.

Abstract

Glucagon-like peptide1 (GLP-1) is secreted from Langerhans cells in response to oral nutrient intake. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a new class of incretin-based anti-diabetic drugs. They function to stimulate insulin secretion while suppressing glucagon secretion. GLP-1-based therapies are now well established in the management of type 2 diabetes mellitus (T2DM), and recent literature has suggested potential applications of these drugs in the treatment of obesity and for protection against cardiovascular and neurological diseases. As we know, along with change in lifestyles, the prevalence of non-alcoholic fatty liver disease (NAFLD) in China is rising more than that of viral hepatitis and alcoholic fatty liver disease, and NAFLD has become the most common chronic liver disease in recent years. Recent studies further suggest that GLP-1RAs can reduce transaminase levels to improve NAFLD by improving blood lipid levels, cutting down the fat content to promote fat redistribution, directly decreasing fatty degeneration of the liver, reducing the degree of liver fibrosis and improving inflammation. This review shows the NAFLD-associated effects of GLP-1RAs in animal models and in patients with T2DM or obesity who are participants in clinical trials.

Keywords: Fat content; Glucagon-like peptide-1 receptor agonists; Inflammation; Liver function; Non-alcoholic fatty liver disease.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Effects of glucagon-like peptide-1 receptor agonist on non-alcoholic fatty liver disease and inflammation. PPAR-α: Peroxisome proliferator-activated receptor; IHL: intrahepatic lipids; AMPK: AMP-activated protein kinase; CRP: C reactive protein; AGEs: Advanced glycation and end products; JNK: c-Jun NH2-terminal kinase; GLP-1RA: Glucagon-like peptide-1 receptor agonist; NAFLD: Non-alcoholic fatty liver disease.

Similar articles

Cited by

References

    1. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705. - PubMed
    1. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther. 2007;113:546–593. - PMC - PubMed
    1. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195–202. - PubMed
    1. Lund A, Knop FK, Vilsbøll T. Emerging GLP-1 receptor agonists. Expert Opin Emerg Drugs. 2011;16:607–618. - PubMed
    1. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42:320–330. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources